Meeting notes from ICAAC. Ritonavir-boosted tipranavir proves beneficial in treatment-experienced patients.
Feinberg
Judith
J
D018791:CD4 Lymphocyte Count; D017326:Clinical Trials, Phase III as Topic; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D006801:Humans; D011725:Pyridines / Q000008:administration & dosage*; D011753:Pyrones / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D019438:Ritonavir / Q000008:administration & dosage*; D013449:Sulfonamides; D019562:Viral Load
D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D019438:Ritonavir; C107201:tipranavir